IS7402A - Ný kristölluð form atorvastatínhálfkalsíums og aðferðir til að framleiða þau, auk nýrra aðferða tilað framleiða atorvastatínhálfkalsíum form I, VIIIog IX - Google Patents
Ný kristölluð form atorvastatínhálfkalsíums og aðferðir til að framleiða þau, auk nýrra aðferða tilað framleiða atorvastatínhálfkalsíum form I, VIIIog IXInfo
- Publication number
- IS7402A IS7402A IS7402A IS7402A IS7402A IS 7402 A IS7402 A IS 7402A IS 7402 A IS7402 A IS 7402A IS 7402 A IS7402 A IS 7402A IS 7402 A IS7402 A IS 7402A
- Authority
- IS
- Iceland
- Prior art keywords
- producing
- calcium
- methods
- new
- forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35718102P | 2002-02-15 | 2002-02-15 | |
| US42532502P | 2002-11-12 | 2002-11-12 | |
| PCT/US2003/005384 WO2003070702A1 (fr) | 2002-02-15 | 2003-02-19 | Nouvelles formes cristallines d'hemi-calcium d'atorvastatine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS7402A true IS7402A (is) | 2004-08-13 |
Family
ID=27760457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS7402A IS7402A (is) | 2002-02-15 | 2004-08-13 | Ný kristölluð form atorvastatínhálfkalsíums og aðferðir til að framleiða þau, auk nýrra aðferða tilað framleiða atorvastatínhálfkalsíum form I, VIIIog IX |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1480950A4 (fr) |
| JP (2) | JP2005519076A (fr) |
| KR (1) | KR100724515B1 (fr) |
| CN (1) | CN100406436C (fr) |
| AU (1) | AU2003217653A1 (fr) |
| CA (1) | CA2475864A1 (fr) |
| DE (1) | DE03713610T1 (fr) |
| ES (1) | ES2241507T1 (fr) |
| HR (1) | HRP20040768A2 (fr) |
| IS (1) | IS7402A (fr) |
| MX (1) | MXPA04007939A (fr) |
| NO (1) | NO20043842L (fr) |
| PL (1) | PL372303A1 (fr) |
| WO (1) | WO2003070702A1 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| US7501450B2 (en) * | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| MXPA04007995A (es) | 2002-02-19 | 2004-11-26 | Teva Pharma | Desolvatacion de solvatos de hemicalcio de atorvastatina. |
| AU2003297594A1 (en) * | 2002-11-28 | 2004-06-23 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
| US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
| CA2672554C (fr) | 2004-07-20 | 2012-01-03 | Warner-Lambert Company Llc | Nouvelles formes de [r-(r*,r*)]-2-(4-fluorophenyl).beta.,.delta.-dihydroxy-5-(isopropyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoatede calcium (2:1) |
| DE05774589T1 (de) * | 2004-07-22 | 2007-08-09 | Teva Pharmaceutical Industries Ltd. | Neue kristallformen von atorvastatin-hemi-calcium und verfahren zu deren herstellung |
| WO2006048894A1 (fr) * | 2004-11-05 | 2006-05-11 | Morepen Laboratories Limited | Nouvelles formes cristallines de calcium d'atorvastatine et procedes de fabrication |
| RO200700700A8 (ro) * | 2005-04-08 | 2015-07-30 | Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag | Procedeu pentru prepararea unei noi forme cristaline polimorfe a sării de hemicalciu a atorvastatinului |
| DE602006014193D1 (de) | 2005-11-21 | 2010-06-17 | Warner Lambert Co | Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-(1-methylethyl)-3-phenyl-4-ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure-magnesium |
| BRPI0610344A2 (pt) | 2005-12-13 | 2016-11-29 | Teva Pharma | forma cristalizada do atorvastatin hemi-calcium, processo para sua preparação, produto famacêutico derivado e seu uso medicinal |
| US20070265456A1 (en) * | 2006-05-09 | 2007-11-15 | Judith Aronhime | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| WO2008108572A1 (fr) * | 2007-03-02 | 2008-09-12 | Dong-A Pharm. Co., Ltd. | Nouvelles formes cristallines de dérivés d'acide pyrrolylheptanoïque |
| KR20120011249A (ko) | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
| KR101324862B1 (ko) * | 2011-07-12 | 2013-11-01 | (주)에이에스텍 | 클로피도그렐 황산수소염의 구형 입자, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
| TWI665190B (zh) | 2013-11-15 | 2019-07-11 | 阿克比治療有限公司 | ｛［５－（３－氯苯基）－３－羥基吡啶－２－羰基］胺基｝乙酸之固體型式，其組合物及用途 |
| CN105055357A (zh) * | 2015-09-25 | 2015-11-18 | 青岛华之草医药科技有限公司 | 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂 |
| KR101723783B1 (ko) * | 2017-02-24 | 2017-04-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL128862A (en) * | 1995-07-17 | 2007-12-03 | Warner Lambert Co | [R - (R * R *)] - 2 - (4 - fluorophenyl) - ß, d - dihydroxy - 5 - (1 - methyl - ethyl) 3 - phenyl - 4 - [(phenamino) carbonyl)] - 1H - Pyrol - 1 - Patenoic acid Hydrogen salt Hydrogen crystalline (Atorostatin) Crystalline hydrate |
| HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| US6087511A (en) | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
| PT1235799E (pt) * | 1999-11-17 | 2005-05-31 | Teva Pharma | Forma polimorfica de atorvastatina-calcio |
| WO2001044181A1 (fr) * | 1999-12-17 | 2001-06-21 | Warner Lambert Research And Development Ireland Limited | Procede pour produire de l'atorvastatine calcique cristallin |
| DE60024133T2 (de) * | 1999-12-17 | 2006-08-03 | Pfizer Science And Technology Ireland Ltd., Dun Laoghaire | Herstellungsverfahren auf industrieller basis von atorvastatin trihydrat hemi-kalziumsalz in kristalliner form |
| IL155734A0 (en) * | 2000-11-03 | 2003-11-23 | Teve Pharmaceutical Ind Ltd | Atorvastatin hemi-calcium form vii |
| IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| CZ20032019A3 (cs) * | 2000-12-27 | 2003-10-15 | Ciba Specialty Chemicals Holding Inc. | Krystalické formy Atorvastatinu |
| WO2002057229A1 (fr) * | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORME V CRISTALLINE DE SEL HEMICALCIQUE D'ACIDE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIQUE (ATORVASTATINE) |
| EA005317B1 (ru) * | 2001-06-29 | 2004-12-30 | УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си | Кристаллические формы [r-(r*,r*)]-2-(4-фторфенил)-бета, дельта-дигидрокси-5-(1-метилэтил)-3-фенил-4-[(фениламино)карбонил]-1h-пиррол-1-гептановой кислоты кальциевой соли (2:1) (аторвастатин) |
| EP1414796A1 (fr) * | 2001-07-30 | 2004-05-06 | Dr. Reddy's Laboratories Ltd. | Formes cristallines vi et vii de calcium d'atorvastatine |
| UA77990C2 (en) * | 2001-12-12 | 2007-02-15 | Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid | |
| CA2491051A1 (fr) * | 2002-09-03 | 2004-03-18 | Morepen Laboratories Limited | Forme vi de calcium d'atorvastatine ou hydrates de cette derniere |
| AU2003297594A1 (en) * | 2002-11-28 | 2004-06-23 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
-
2003
- 2003-02-19 PL PL03372303A patent/PL372303A1/xx not_active Application Discontinuation
- 2003-02-19 CN CNB038082071A patent/CN100406436C/zh not_active Expired - Fee Related
- 2003-02-19 CA CA002475864A patent/CA2475864A1/fr not_active Abandoned
- 2003-02-19 WO PCT/US2003/005384 patent/WO2003070702A1/fr active Application Filing
- 2003-02-19 EP EP03713610A patent/EP1480950A4/fr not_active Withdrawn
- 2003-02-19 DE DE03713610T patent/DE03713610T1/de active Pending
- 2003-02-19 AU AU2003217653A patent/AU2003217653A1/en not_active Abandoned
- 2003-02-19 JP JP2003569609A patent/JP2005519076A/ja not_active Withdrawn
- 2003-02-19 ES ES03713610T patent/ES2241507T1/es active Pending
- 2003-02-19 KR KR1020047012591A patent/KR100724515B1/ko not_active IP Right Cessation
- 2003-02-19 MX MXPA04007939A patent/MXPA04007939A/es unknown
-
2004
- 2004-08-13 IS IS7402A patent/IS7402A/is unknown
- 2004-08-25 HR HR20040768A patent/HRP20040768A2/hr not_active Application Discontinuation
- 2004-09-14 NO NO20043842A patent/NO20043842L/no not_active Application Discontinuation
-
2009
- 2009-06-08 JP JP2009137400A patent/JP2009235083A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA04007939A (es) | 2004-11-26 |
| KR100724515B1 (ko) | 2007-06-04 |
| KR20040081202A (ko) | 2004-09-20 |
| EP1480950A1 (fr) | 2004-12-01 |
| JP2005519076A (ja) | 2005-06-30 |
| CN100406436C (zh) | 2008-07-30 |
| CA2475864A1 (fr) | 2003-08-28 |
| AU2003217653A1 (en) | 2003-09-09 |
| CN1646490A (zh) | 2005-07-27 |
| EP1480950A4 (fr) | 2005-05-18 |
| ES2241507T1 (es) | 2005-11-01 |
| JP2009235083A (ja) | 2009-10-15 |
| NO20043842L (no) | 2004-09-14 |
| HRP20040768A2 (en) | 2005-06-30 |
| WO2003070702A1 (fr) | 2003-08-28 |
| DE03713610T1 (de) | 2005-10-20 |
| PL372303A1 (en) | 2005-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS7402A (is) | Ný kristölluð form atorvastatínhálfkalsíums og aðferðir til að framleiða þau, auk nýrra aðferða tilað framleiða atorvastatínhálfkalsíum form I, VIIIog IX | |
| IS8122A (is) | Aðferð til að framleiða N-útskipt 2-sýanópýrrólídín | |
| IS8447A (is) | Aðferð til að framleiða gamma-karboxýleruð prótín | |
| IS7261A (is) | N-adamantýlmetýlafleiður og milliefni sem lyfjablöndur og aðferðir til að framleiða þær | |
| DK1654438T3 (da) | Fremgangsmåde til naturgasproduktion | |
| IS7351A (is) | Kristölluð karvedílól á föstu formi og aðferðir til að framleiða þau | |
| NO20034285L (no) | Fremgangsmate for fremstilling av syntesegass | |
| DE60321130D1 (de) | Variation von parametern zur neurostimulation | |
| IS7467A (is) | Lansóprasólfjölgervingar og aðferðir við að framleiða þá | |
| EP1809613A4 (fr) | Procedes pour fabriquer des derives de 2,6-diaryle piperidine | |
| IS8416A (is) | Aðferð við framleiðslu á CCR-2 mótlyfi | |
| DK1890570T3 (da) | Tandbørstehoved og fremgangsmåde til fremstilling deraf | |
| DK1518827T3 (da) | Krystalliseret IM-12-faststof og fremgangsmåde til fremstilling heraf | |
| AU2003261191A8 (en) | Methods for producing biopolymers | |
| DK1353923T3 (da) | Forbedret fremgangsmåde til syntese af carbapenem | |
| IS7069A (is) | Aðferð til að framleiða zaleplon | |
| ATE424892T1 (de) | Verfahren zur herstellung von derivaten des 4a,5, 9,10,11,12-hexahydrobenzofuro ä3a,3,2üä 2 ü- benzazepins | |
| HK1081532A1 (en) | Method for the production of monoalkylamino ketones | |
| EP1600511A4 (fr) | Procede de traitement de maladie ischemique | |
| NO20043760L (no) | Fremgangsmate til fremstilling av olefiner | |
| NO20043568D0 (no) | Fremgangsmate for a fremstille citalopram | |
| PL356895A1 (en) | Method of manufacture of n-(4-cyano-3-trifluoromethylo phenylo)-2,3-epoxy-2-methyl prop anamide | |
| ITMI20021432A0 (it) | Metodo per produrre cefalosporine | |
| GB0218706D0 (en) | Method of voice authentication | |
| PL351600A1 (en) | Method of obtaining modified fine-crystalline chitozane |